Published in J Neural Transm (Vienna) on January 01, 1998
The three modern faces of mercury. Environ Health Perspect (2002) 3.33
Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. Eur J Nutr (2007) 1.45
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci (2015) 1.07
Mercury-induced toxicity of rat cortical neurons is mediated through N-Methyl-D-Aspartate receptors. Mol Brain (2012) 0.96
Association between dental amalgam fillings and Alzheimer's disease: a population-based cross-sectional study in Taiwan. Alzheimers Res Ther (2015) 0.89
Mercury Reduces the Enzymatic Activity of Neprilysin in Differentiated SH-SY5Y Cells. Toxicol Sci (2015) 0.75
Genetic variation associated with hypersensitivity to mercury. Toxicol Int (2015) 0.75
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology (2006) 3.68
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Treatment for Alzheimer's disease? N Engl J Med (1992) 2.72
Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science (1992) 2.50
Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem (2001) 2.40
Head injury and the risk of AD in the MIRAGE study. Neurology (2000) 2.34
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension (1994) 2.28
Captured by art. Science (2001) 2.21
A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab (2012) 2.16
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Prevention of preterm birth: early detection and aggressive treatment with terbutaline. South Med J (1993) 2.10
A Neural Dissociation within Language: Evidence that the Mental Dictionary Is Part of Declarative Memory, and that Grammatical Rules Are Processed by the Procedural System. J Cogn Neurosci (1997) 2.04
White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging (2010) 2.01
Risk for periodontal disease in patients with longstanding rheumatoid arthritis. Arthritis Rheum (1997) 2.00
Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report. Pharmacopsychiatry (2006) 1.94
Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol (2000) 1.93
Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci (2000) 1.90
Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A (1992) 1.86
Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology (1996) 1.85
Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol (1999) 1.81
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol (1996) 1.66
The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci (2000) 1.65
Beta-adrenergic mechanisms in action tremor. N Engl J Med (1975) 1.65
Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem (1993) 1.64
Transmission of scrapie by steel-surface-bound prions. Mol Med (2001) 1.63
High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet (2000) 1.61
Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol (1989) 1.54
Amalgam studies: disregarding basic principles of mercury toxicity. Int J Hyg Environ Health (2004) 1.53
Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity. Arch Neurol (1988) 1.49
Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol (1995) 1.48
The effect of alcohol on essential tremor. Neurology (1975) 1.46
No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Genomics (1996) 1.45
Current pharmacotherapy for Alzheimer's disease. Annu Rev Med (2006) 1.45
Determinants of vitamin D status in a general population of Danish adults. Bone (2011) 1.45
Oral choline administration to patients with tardive dyskinesia. N Engl J Med (1977) 1.43
Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol (1995) 1.42
Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J Intern Med (2012) 1.41
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost (1995) 1.41
Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos Int (1993) 1.39
Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. AJNR Am J Neuroradiol (1995) 1.31
Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem (2001) 1.30
The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med (2006) 1.29
Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci U S A (1993) 1.29
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology (2005) 1.26
Segregation analysis reveals evidence of a major gene for Alzheimer disease. Am J Hum Genet (1991) 1.25
Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology (2001) 1.25
Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology (1999) 1.24
Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int (1993) 1.22
Visual dysfunction in Alzheimer's disease: relation to normal aging. Ann Neurol (1991) 1.21
Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging (2001) 1.19
Parathyroid hormone and bone healing. Calcif Tissue Int (2010) 1.18
Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol (2001) 1.18
Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann Neurol (1989) 1.17
Lecithin can suppress tardive dyskinesia. N Engl J Med (1978) 1.14
Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci (1996) 1.13
Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol (2009) 1.12
Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol (2000) 1.12
Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab (2003) 1.12
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability. J Med Chem (2000) 1.11
Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol (2001) 1.10
Intact acquisition and long-term retention of mirror-tracing skill in Alzheimer's disease and in global amnesia. Behav Neurosci (1993) 1.10
The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (2000) 1.09
A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol (1997) 1.08
Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem (1996) 1.08
Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull (1998) 1.08
Clinical and morphological findings on mustard gas [bis(2-chloroethyl)sulfide] poisoning. J Forensic Sci (1991) 1.08
Remote memory function in Alzheimer's disease and Parkinson's disease. Brain (1988) 1.08
Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development. Mech Dev (2000) 1.07
Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment. Ann Neurol (1995) 1.07
Effects of hydrogen peroxide-containing bleaching agents on the morphology of human enamel. Quintessence Int (1996) 1.07
Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol (2000) 1.06
Loss of glycosylation associated with the T183A mutation in human prion disease. Acta Neuropathol (2004) 1.06
Lecithin consumption raises serum-free-choline levels. Lancet (1977) 1.05
Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci (1995) 1.04
An experimental study of cerebellar dyskinesia in the rhesus monkey. Brain (1967) 1.03
Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav (2006) 1.03
Spatial vision in Alzheimer's disease. General findings and a case report. Arch Neurol (1985) 1.03
Visual dysfunction predicts cognitive deficits in Alzheimer's disease. Optom Vis Sci (1995) 1.02
Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci (2001) 1.01
Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol Aging (2002) 1.01
Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci U S A (1995) 1.01
Spatial, but not object, delayed response is impaired in early Parkinson's disease. Neuropsychology (1997) 0.99
Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet (1998) 0.99
Interactive computer-based cognitive training in patients with Alzheimer's disease. J Psychiatr Res (1997) 0.98
Semantic impairment and anomia in Alzheimer's disease. Brain Lang (1986) 0.98